118 Chapter 4 Supplementary Figure 1: Immunological events overview for narcolepsy type 1 excluding those with a clinical diagnosis. If no exact timing of the event was known, this individual was not included in column 3. EBV = Epstein–Barr virus; ICSD-3 = international classification of sleep disorders - third edition; NT1 = narcolepsy type 1. Immunological events before narcolepsy type 2 and idiopathic hypersomnia onset (excluding people with a clinical diagnosis) Infection and/or influenza vaccination history was known in 44 individuals with narcolepsy type 2 or idiopathic hypersomnia, of which the infection history was known in 28 (Supplementary Figure 2A) and the influenza vaccination history in 34 (Supplementary Figure 2B). Infection and/or influenza vaccination were reported before developing narcolepsy type 2 or idiopathic hypersomnia in 20/44 individuals (45.4%). Among the people with narcolepsy type 2 or idiopathic hypersomnia, four individuals reported an infection and influenza vaccination before the onset of their hypersomnolence disorder. These individuals were included in Supplementary Figure 2 in the group of immunological events closest to their start of EDS (for all people, this was an infection). Infection history An infection before onset of narcolepsy type 2 or idiopathic hypersomnia was reported in 17/28 (60.7%; Supplementary Figure 2A). Other respiratory
RkJQdWJsaXNoZXIy MjY0ODMw